Talk:Andexanet alfa
Latest comment: 6 years ago by Recbcd in topic Brand versus generic
| This is the talk page for discussing improvements to the Andexanet alfa article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Andexanet alfa.
|
 | The following Wikipedia contributors may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
|
 | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
Brand versus generic
editThis is a brand name "Andexxa"[1]
"Andexanet alfa" is the proposed INN[2]
Doc James (talk · contribs · email) 19:55, 5 November 2018 (UTC)
- Actually, "Andexanet alfa" is no longer an appropriate INN for "Andexxa" in US [3]. It is very likely that INN will be changed in EU too. --Recbcd (talk) 15:58, 13 November 2018 (UTC)